Drugs / IL13(EQ)BBzeta/CD19t+ T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04510051 | Dec 2020 → Feb 2027 expected | brain cancer | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL13(EQ)BBzeta/CD19t+ T cells | “Patients then receive autologous IL13(EQ)BBzeta/CD19t+ T cells intraventricularly over 5 minutes QW on day 0.” NCT04510051 ↗ |
| Modality | Cell therapy | “Cellular immunotherapy (IL13(EQ)BBzeta/CD19t+ T cells) are brain-tumor specific cells” NCT04510051 ↗ |
| Target | IL13RA2 | “IL13Ralpha2-specific hinge-optimized 41BB-co-stimulatory chimeric antigen receptor” NCT04510051 ↗ |